Cargando…
Strategies for Dodging the Obstacles in CAR T Cell Therapy
Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphom...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047470/ https://www.ncbi.nlm.nih.gov/pubmed/33869011 http://dx.doi.org/10.3389/fonc.2021.627549 |
_version_ | 1783679045750226944 |
---|---|
author | Safarzadeh Kozani, Pooria Safarzadeh Kozani, Pouya Rahbarizadeh, Fatemeh Khoshtinat Nikkhoi, Shahryar |
author_facet | Safarzadeh Kozani, Pooria Safarzadeh Kozani, Pouya Rahbarizadeh, Fatemeh Khoshtinat Nikkhoi, Shahryar |
author_sort | Safarzadeh Kozani, Pooria |
collection | PubMed |
description | Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. However, CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings. Adverse events such as cytokine release syndrome (CRS), neurotoxicity, graft rejection, on-target off-tumor toxicities, and tumor relapse have tied the rescuing hands of CAR T cell therapies. Moreover, in the case of solid tumor treatment, CAR T cell therapies have not yielded encouraging results mainly due to challenges such as the formidable network of the tumor microenvironments (TME) that operates in a suppressive fashion resulting in CAR T cell dysfunction. In this review, we tend to shine a light on emerging strategies and solutions for addressing the mentioned barriers. These solutions might dramatically help shorten the gap between a successful clinical outcome and the hope for it. |
format | Online Article Text |
id | pubmed-8047470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80474702021-04-16 Strategies for Dodging the Obstacles in CAR T Cell Therapy Safarzadeh Kozani, Pooria Safarzadeh Kozani, Pouya Rahbarizadeh, Fatemeh Khoshtinat Nikkhoi, Shahryar Front Oncol Oncology Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. However, CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings. Adverse events such as cytokine release syndrome (CRS), neurotoxicity, graft rejection, on-target off-tumor toxicities, and tumor relapse have tied the rescuing hands of CAR T cell therapies. Moreover, in the case of solid tumor treatment, CAR T cell therapies have not yielded encouraging results mainly due to challenges such as the formidable network of the tumor microenvironments (TME) that operates in a suppressive fashion resulting in CAR T cell dysfunction. In this review, we tend to shine a light on emerging strategies and solutions for addressing the mentioned barriers. These solutions might dramatically help shorten the gap between a successful clinical outcome and the hope for it. Frontiers Media S.A. 2021-04-01 /pmc/articles/PMC8047470/ /pubmed/33869011 http://dx.doi.org/10.3389/fonc.2021.627549 Text en Copyright © 2021 Safarzadeh Kozani, Safarzadeh Kozani, Rahbarizadeh and Khoshtinat Nikkhoi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Safarzadeh Kozani, Pooria Safarzadeh Kozani, Pouya Rahbarizadeh, Fatemeh Khoshtinat Nikkhoi, Shahryar Strategies for Dodging the Obstacles in CAR T Cell Therapy |
title | Strategies for Dodging the Obstacles in CAR T Cell Therapy |
title_full | Strategies for Dodging the Obstacles in CAR T Cell Therapy |
title_fullStr | Strategies for Dodging the Obstacles in CAR T Cell Therapy |
title_full_unstemmed | Strategies for Dodging the Obstacles in CAR T Cell Therapy |
title_short | Strategies for Dodging the Obstacles in CAR T Cell Therapy |
title_sort | strategies for dodging the obstacles in car t cell therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047470/ https://www.ncbi.nlm.nih.gov/pubmed/33869011 http://dx.doi.org/10.3389/fonc.2021.627549 |
work_keys_str_mv | AT safarzadehkozanipooria strategiesfordodgingtheobstaclesincartcelltherapy AT safarzadehkozanipouya strategiesfordodgingtheobstaclesincartcelltherapy AT rahbarizadehfatemeh strategiesfordodgingtheobstaclesincartcelltherapy AT khoshtinatnikkhoishahryar strategiesfordodgingtheobstaclesincartcelltherapy |